ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity ...
The next-generation multispecific antibody therapeutics in development will focus on enhancing safety enhancing tumor selectivity by conditional activation with 'conditionally-active multispecific ...
Recule, a biotechnology company pioneering RNA therapies, and GBI Biomanufacturing, a leading contract development and manufacturing organization (CDMO), today announced a strategic partnership to ...
Protein therapeutics, particularly monoclonal antibodies, have become a cornerstone of modern medicine, offering targeted treatments for various diseases, including cancers and autoimmune disorders.
The next-generation multispecific antibody therapeutics in development will focus on enhancing safety enhancing tumor selectivity by conditional activation with 'conditionally-active multispecific ...
The characterization of biological macromolecules, such as proteins and antibodies, is crucial for understanding their structure, function, and potential therapeutic applications. Recent research ...
Recent results raise hope of new "broad, pan-tumor platform" like Keytruda. The emerging drugs are bispecific antibodies that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback